Effect comparison of two anti-vascular endothelial growth factor drugs combined with trabeculectomy in the treatment of neovascular glaucoma

ObjectiveTo compare the effects and complications between two kinds of anti-vascular endothelial growth factor(VEGF) monoclonal antibodies(ranibizumab and conbercept) in the treatment of neovascular glaucoma(NVG).

MethodsFourty-nine NVG patients were divided into the leizumab group(23 cases) and conbercept group(26 cases) according to the treatment with different anti-VEGF drug, and the clinic data of two groups were retrospectively analyzed.

ResultsThe differences of intraocular pressure(IOP) between two groups at different time-points were not statistically significant(P>0.05).The IOP in two groups after 1 week, 2 weeks, 3 weeks and 1 month of operation were significantly lower than that before and after injection(P < 0.01).After treatment, the differences of vision, iris neovascularization and complications between two groups were not statistically significant(P>0.05).

ConclusionsThe intravitreal injection of anti-VEGF drugs combined with trabeculectomy is a safe and effective treatment.On the premise of similar efficacy, conbercept is a better choice than ranibizumab.